Feature | September 05, 2013

Cardiac Resychronization Therapy Fails for Certain Heart Failure Patients

The EchoCRT trial was ended early to prevent harm to patients

September 5, 2013 — Researchers announced this week that an attempt to expand cardiac resynchronization therapy (CRT) to include more patients with heart failure has failed and an international clinical trial ended early to prevent potential harm to patients. 
 
The Echocardiography Guided Cardiac Resynchronization Therapy (EchoCRT) is the largest international, multicentre, prospective, randomized, double-blind, clinical trial of its kind. Results of the trial are available online by the New England Journal of Medicine and were presented during this week’s Late Breaking Clinical Trials session at the European Society of Cardiology Congress in Amsterdam, Netherlands.
 
The trial found the widespread off-label use of CRT in patients with narrow QRS should no longer be used as an option for patients with a QRS below 130 milliseconds, regardless of mechanical dyssynchrony. This trial serves as a reminder that in clinical medicine adequately powered definitive clinical outcome trials are needed before we expand the use of an apparently favorable therapy.
 
“Cardiac resynchronization therapy is a proven treatment for people who have a type of heart failure that includes an electrical abnormality, or a wide QRS complex,” said William Abraham, M.D., director of the division of cardiovascular medicine at The Ohio State University Wexner Medical Center and national co-principal investigator of the study. “We noticed some cardiologists were also trying CRT in heart failure patients who did not have this electrical abnormality, however no large studies had tested the use of CRT in this way.”
 
In 2008, cardiovascular researchers at 115 centers in Europe, Australia and the United States teamed up to test the safety and efficacy of CRT in heart failure patients who had a narrow QRS complex. Patients were enrolled in the study if they had an ejection fraction of 35 percent or less, a narrow QRS duration of 130 milliseconds or less and echocardiographic evidence of a left ventricular dyssynchrony. A total of 809 study participants underwent implantation of a cardiac resynchronization device with defibrillator capability developed by Biotronik. Half (404) were randomized to have CRT turned on while the other half (405) did not receive CRT. All study participants had the defibrillator capability turned on.
 
After following each participant an average of 19 months, the trial was stopped in March on the basis of futility and potential for harm. Researchers recorded 45 deaths and 224 hospitalizations for worsening heart failure in the CRT group compared to 26 deaths and 194 hospitalizations in the control group. 
 
“Not only did cardiac resynchronization not help these patients with systolic heart failure, but the data showed the potential for harm,” said Abraham. “This is a landmark trial in CRT and heart failure because it tells us we should not use this therapy in this group of patients.”
 
Heart failure occurs when the heart does not pump blood efficiently, most often due to a weak heart muscle. Patients suffer from shortness of breath, fatigue, swelling and reduced quality of life. According to the American Heart Association, about 5.7 million Americans have heart failure and it accounts for about 1 million hospital admissions each year at an estimated societal cost of $32 billion.
 
“We’re always looking for better treatments for patients with heart failure to improve their quality of life and reduce their hospitalizations,” said  Ayesha Hasan, M.D., a heart failure cardiologist at Ohio State’s Richard M. Ross Heart Hospital and the lead principal investigator at Ohio State. “We now know expanding the use of CRT in this population of patients is not a positive solution.”
 
Abraham says researchers are still investigating why CRT did not work for this group of patients, to better understand the benefits and challenges of this treatment option.
 
“The EchoCRT trial evaluated an important question for daily clinical practice.  The results will help to guide physicians’ treatment decisions for heart failure patients moving forwards.” said co-lead investigator Johannes Holzmeister, M.D., from University Hospital in Zurich, Switzerland.
Biotronik funded the FDA-approved trial. Abraham is a paid consultant for the company.
 
For more information: bit.ly/1buTeHk
 

Related Content

warfarin, atrial fibrillation, kidney failure, HRS 2016
News | Antiplatelet and Anticoagulation Therapies| May 06, 2016
Atrial fibrillation patients taking warfarin are at higher risk of developing kidney failure if anticoagulation levels...
SCAI 2016, PCI, bleeding risk, bivalirudin, NCDR risk calculator, clinical trial
News | Antiplatelet and Anticoagulation Therapies| May 06, 2016
The largest risk-directed study by a national hospital system demonstrates a 40 percent decline in bleeding events for...
CSI, Cardiovascular Systems Inc, Diamondback 360 Coronary Orbital Atherectomy System, OAS, ORBIT II study, three-year results, SCAI 2016
News | Atherectomy Devices| May 06, 2016
May 6, 2016 — Cardiovascular Systems Inc.
TOBA-BTK study, twelve-month results, SCAI 2016, Tack Endovascular System, critical limb ischemia
News | Peripheral Arterial Disease (PAD)| May 05, 2016
Intact Vascular Inc. announced that positive twelve-month results from its Tack Optimized Balloon Angioplasty – Below-...
Acutus Medical, AcQMap EP Imaging and Mapping System, CE Mark
News | EP Mapping and Imaging Systems| May 04, 2016
Acutus Medical announced CE Mark approval for its AcQMap High Resolution Imaging and Mapping System and AcQMap Catheter...
Biotronik, FDA, MR Conditional CRT devices, Iperia HF-T, defibrillator, ProMRI
Technology | Cardiac Resynchronization Therapy Devices (CRT)| May 03, 2016
Biotronik announced U.S. Food and Drug Administration (FDA) approval of Iperia ProMRI HF-T, a cardiac resynchronization...
radiation dose in the cath lab
News | Radiation Dose Management| May 02, 2016
May 2, 2016 — Starting at the Society for Cardiovascular Angiography and Interventions (SCAI) 2016 annual meeting May
AtriCure, AtriClip PRO2 LAA Exclusion System, left atrial appendage, FDA clearance
Technology | Left Atrial Appendage (LAA) Occluders| April 29, 2016
April 29, 2016 — AtriCure Inc. announced U.S.
microtubules, heartbeat mechanics, Perelman School of Medicine study

Microtubules in a cardiomyocyte at rest (top) and when compressed. Image courtesy of the lab of Ben Prosser, Ph.D., Perelman School of Medicine, University of Pennsylvania

News | EP Lab| April 29, 2016
Using new high-resolution microscopy, researchers have found that molecular struts called microtubules (MT) interact...
Boston Scientific, FDA, ImageReady MR-Conditional Pacing System
Technology | EP Lab| April 28, 2016
Boston Scientific has received U.S. Food and Drug Administration (FDA) approval for a suite of products deemed safe for...
Overlay Init